Dealing with the pressures of COVID and the transition to SaaS, Sopheon has delivered prelims as per the January trading update, maintaining revenue in line with FY19 and controlling costs, with $1.8m of positive free cash flow and net cash of $21.7m. ARR and TCV won in the period grew (13% and 25% respectively), and the pipeline is the strongest ever. Visibility for delivery of revenue expectations for FY21 has already hit $24.5m, equivalent to 74% of our reintroduced revenue forecast of $33m f ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sopheon - COVID can’t stop TCV and ARR growth
- Published:
24 Mar 2021 -
Author:
Andrew Darley -
Pages:
14
Dealing with the pressures of COVID and the transition to SaaS, Sopheon has delivered prelims as per the January trading update, maintaining revenue in line with FY19 and controlling costs, with $1.8m of positive free cash flow and net cash of $21.7m. ARR and TCV won in the period grew (13% and 25% respectively), and the pipeline is the strongest ever. Visibility for delivery of revenue expectations for FY21 has already hit $24.5m, equivalent to 74% of our reintroduced revenue forecast of $33m f ....